Teva Pharmaceuticals announced Sept. 28 that the U.S. Food and Drug Administration approved Degevma (denosumab-adet), a biosimilar to Amgen's Xgeva. The drug is approved for all of Xgeva's uses, including preventing fractures and other bone complications in adults whose cancer has spread to the bone.
For patients with advanced breast, prostate, lung, or other solid tumors, and for people with multiple myeloma, bone complications can mean fractures, spinal cord compression, surgery, or radiation. Xgeva is one of the standard drugs used to lower that risk, and patients may receive it for months or years.
